Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Xijing Hospital: Clinical Trials & FDA Approval Profile

Xijing Hospital (Global / Institutional) sponsors 44 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 26 active protocols (13 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.5%
Median Closed Enrollment vs National (145 pts)60 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Xijing Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)44
Active Pipeline (Recruiting Now)26 (13)
Completed vs Stopped Early8 / 2 (4.5%)
Median Closed Actual Enrollment60 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Xijing Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07116733Desflurane vs. Propofol for Cardiac AnesthesiaPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Xijing Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI